Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cancer discovery

Showing results (311-320 of 4,675) with videos related to

Pageof 468
Sort By:
Cancer Discovery|March 8, 2022
IDH1 Inhibition Reawakens the Immune Response against CholangiocarcinomaYan Zhu, Lawrence N Kwong
Cancer Discovery|June 15, 2018
Immunotherapy Resistance by Inflammation-Induced DedifferentiationArnav Mehta, Yeon Joo Kim, Lidia Robert, et al.
Cancer Discovery|September 2, 2018
Broad Genomic Testing in NSCLC: No Survival Benefit?
Cancer Discovery|May 27, 2018
<i>NRG1</i> Fusions in <i>KRAS</i> Wild-Type Pancreatic CancerChristoph Heining, Peter Horak, Sebastian Uhrig, et al.
Cancer Discovery|September 3, 2016
Activating TCR Signaling to Thwart T-ALLFrançois Lemonnier, Tak W Mak
Cancer Discovery|September 3, 2016
Developing EZH2-Targeted Therapy for Lung CancerArthur E Frankel, Xin Liu, John D Minna
Cancer Discovery|September 3, 2016
High-Throughput Testing of Novel-Novel Combination Therapies for Cancer: An Idea Whose Time Has ComeUciane K Scarlett, Dennis C Chang, Thomas J Murtagh, et al.
Cancer Discovery|September 8, 2016
Bursts of Chromosome Changes Drive TNBC
Cancer Discovery|September 9, 2016
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast CancerXiuning Le, Rajee Antony, Pedram Razavi, et al.
Cancer Discovery|September 16, 2016
Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase InhibitionMary T Scott, Koorosh Korfi, Peter Saffrey, et al.
Pageof 468

Showing results (311-320 of 4,675) with videos related to

Sort By:
Pageof 468
Cancer Discovery|March 8, 2022
IDH1 Inhibition Reawakens the Immune Response against CholangiocarcinomaYan Zhu, Lawrence N Kwong
Cancer Discovery|June 15, 2018
Immunotherapy Resistance by Inflammation-Induced DedifferentiationArnav Mehta, Yeon Joo Kim, Lidia Robert, et al.
Cancer Discovery|September 2, 2018
Broad Genomic Testing in NSCLC: No Survival Benefit?
Cancer Discovery|May 27, 2018
<i>NRG1</i> Fusions in <i>KRAS</i> Wild-Type Pancreatic CancerChristoph Heining, Peter Horak, Sebastian Uhrig, et al.
Cancer Discovery|September 3, 2016
Activating TCR Signaling to Thwart T-ALLFrançois Lemonnier, Tak W Mak
Cancer Discovery|September 3, 2016
Developing EZH2-Targeted Therapy for Lung CancerArthur E Frankel, Xin Liu, John D Minna
Cancer Discovery|September 3, 2016
High-Throughput Testing of Novel-Novel Combination Therapies for Cancer: An Idea Whose Time Has ComeUciane K Scarlett, Dennis C Chang, Thomas J Murtagh, et al.
Cancer Discovery|September 8, 2016
Bursts of Chromosome Changes Drive TNBC
Cancer Discovery|September 9, 2016
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast CancerXiuning Le, Rajee Antony, Pedram Razavi, et al.
Cancer Discovery|September 16, 2016
Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase InhibitionMary T Scott, Koorosh Korfi, Peter Saffrey, et al.
Pageof 468